Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
2(40%)
Results Posted
67%(2 trials)

Phase Distribution

Ph phase_1
1
20%
Ph phase_2
2
40%

Phase Distribution

1

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
Phase 2Efficacy & side effects
2(66.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

5

all time

Status Distribution
Active(2)
Completed(3)

Detailed Status

Completed3
Recruiting1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
2
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 11 (33.3%)
Phase 22 (66.7%)

Trials by Status

completed360%
recruiting120%
active_not_recruiting120%

Recent Activity

2 active trials
Showing 5 of 5
recruiting

Observational Study of the Effectiveness of Funded Drugs for Genitourinary Tumors.

NCT06724159
completed

Immune-checkpoint Inhibitors and Surrogate Endpoints in Cancer Trials (SURROGATE-ICI)

NCT03963518
active_not_recruitingphase_2

Neoadjuvant Nivolumab With and Without Urelumab in Cisplatin-Ineligible or Chemotherapy-refusing Patients With Muscle-Invasive Urothelial Carcinoma of the Bladder

NCT02845323
completedphase_2

Nivolumab With or Without Ipilimumab in Advanced Metastatic Cancer

NCT03651271
completedphase_1

A Longitudinal Assessment of Tumor Evolution in Patients With Brain Cancer

NCT03425292

Clinical Trials (5)

Showing 5 of 5 trials
NCT06724159

Observational Study of the Effectiveness of Funded Drugs for Genitourinary Tumors.

Recruiting
NCT03963518

Immune-checkpoint Inhibitors and Surrogate Endpoints in Cancer Trials (SURROGATE-ICI)

Completed
NCT02845323Phase 2

Neoadjuvant Nivolumab With and Without Urelumab in Cisplatin-Ineligible or Chemotherapy-refusing Patients With Muscle-Invasive Urothelial Carcinoma of the Bladder

Active Not Recruiting
NCT03651271Phase 2

Nivolumab With or Without Ipilimumab in Advanced Metastatic Cancer

Completed
NCT03425292Phase 1

A Longitudinal Assessment of Tumor Evolution in Patients With Brain Cancer

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5